• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ETANERCEPT Drug Record

  • Summary
  • Interactions
  • Claims
  • ETANERCEPT chembl:CHEMBL1201572 ApprovedImmunotherapy

    Alternate Names:

    GP-2015
    RHU-TNFR:FC
    GP2015C
    LBEC0101
    ENBREL
    ETANERCEPT
    TNFR-IMMUNOADHESIN
    L04AB01
    GP2015
    HD203
    RHU TNFR:FC
    BENEPALI
    FC
    CD120B
    TUMOR NECROSIS FACTOR RECEPTOR TYPE II
    TUMOR NECROSIS FACTOR RECEPTOR 2
    TNF-R2
    P80 TNF-ALPHA RECEPTOR
    RHU TNFR
    TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B PRECURSOR
    P75
    chembl:CHEMBL1201572
    chemidplus:185243-69-0
    drugbank:00005
    rxcui:214555

    Drug Info:

    Drug Class immunomodulatory agents
    Year of Approval 1998
    Drug Class antirheumatic agents
    FDA Approval approved
    Drug Class fusion protein
    Drug Indications antiinflammatory agent,DMARD
    (3 More Sources)

    Publications:

    Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Xing-Rong W et al., 2018, Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis., Medicine (Baltimore)
    Park et al., 1999, Structural basis for self-association and receptor recognition of human TRAF2., Nature
    Calabrese, 1999, Rheumatoid arthritis and primary care: the case for early diagnosis and treatment., J Am Osteopath Assoc
    Sandborn et al., 1999, Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety., Inflamm. Bowel Dis.
    Moreland, 1999, Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis., Cleve Clin J Med
    Grell et al., 1999, Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF., EMBO J.
    Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
    Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
    Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
    Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
    Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
    Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
    O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
    Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
    Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
    Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
    Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
    Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
    Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
    Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
    Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
    Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
    Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum
    Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
    Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
    Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
    Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
    Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
    Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
    Agnholt et al., 2003, The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures., Cytokine
    Julià A et al., 2014, PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis., Pharmacogenomics
    Julià A et al., 2015, Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis., Pharmacogenomics J
    Acosta-Colman I et al., 2013, GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis., Pharmacogenomics
    Ovejero-Benito MC et al., 2017, Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis., Pharmacogenomics
    Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
    Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
    Xu et al., 2008, Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms., Toxicology
    Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics
    van den Reek JMPA et al., 2017, Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis., Br J Dermatol
  • ETANERCEPT   CD84

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27564082


    Sources:
    PharmGKB

  • ETANERCEPT   SLCO1C1

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25493569 25403996 23651021


    Sources:
    PharmGKB

  • ETANERCEPT   FCGR2A

    Interaction Score: 3.25

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    27044681 24048425 15457442 15526004 27463856 19128982


    Sources:
    PharmGKB

  • ETANERCEPT   TRAF1

    Interaction Score: 2.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007924


    Sources:
    PharmGKB

  • ETANERCEPT   TNFRSF1A

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22480748


    Sources:
    PharmGKB

  • ETANERCEPT   KLRD1

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26453102


    Sources:
    PharmGKB

  • ETANERCEPT   TNFRSF1B

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11752352 30075559


    Sources:
    PharmGKB

  • ETANERCEPT   ATP5F1E

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26307125


    Sources:
    PharmGKB

  • ETANERCEPT   IL12B

    Interaction Score: 1.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28470127


    Sources:
    PharmGKB

  • ETANERCEPT   TNF

    Interaction Score: 1.24

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor
    Trial Name Enbrel

    PMIDs:
    10206649 10405518 10338381 10375846 11752352 10357816 26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ETANERCEPT   STAT4

    Interaction Score: 1.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ETANERCEPT   FCGR3A

    Interaction Score: 0.95

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    15457442 15526004 27044681 24048425 27463856 19128982


    Sources:
    PharmGKB

  • ETANERCEPT   HLA-E

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ETANERCEPT   PTPRC

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007924 20309874


    Sources:
    PharmGKB

  • ETANERCEPT   PSORS1C1

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ETANERCEPT   GHRL

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18400355


    Sources:
    NCI

  • ETANERCEPT   IL6

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24253594


    Sources:
    PharmGKB

  • ETANERCEPT   CSF2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12906870


    Sources:
    NCI

  • ETANERCEPT   HLA-DRB1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: ETANERCEPT

    • Version: 01-August-2011

    Alternate Names:
    ETANERCEPT Primary Drug Name

    Drug Info:
    Drug Class antirheumatic agents
    Year of Approval 1998
    Drug Class immunomodulatory agents

    Publications:

  • TdgClinicalTrial: ETANERCEPT

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,DMARD
    Drug Class fusion protein
    FDA Approval approved

    Publications:

  • NCI: ETANERCEPT

    • Version: 14-September-2017

    Alternate Names:
    C2381 NCI drug code

    Drug Info:

    Publications:
    Agnholt et al., 2003, The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures., Cytokine
    Xu et al., 2008, Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms., Toxicology

  • PharmGKB: etanercept

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Ovejero-Benito MC et al., 2017, Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis., Pharmacogenomics
    Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
    Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics

  • TTD: Etanercept

    • Version: 2020.06.01

    Alternate Names:
    D0I5QX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201572

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201572

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21